Navigation Links
TB-drugome provides new targets for anti-tuberculosis drug discovery
Date:11/8/2010

Researchers at the University of California, San Diego School of Medicine and the University of Leeds have linked hundreds of federally approved drugs to more than 1,000 proteins in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), opening new avenues to repurpose these drugs to treat TB.

The study was published Nov. 4 in PLoS Computational Biology.

"Tuberculosis is currently one of the most widely spread infectious diseases, with an estimated one-third of the world's population infected and between one and two million people dying each year from the disease," said Philip Bourne, PhD, professor of pharmacology at UCSD's Skaggs School of Pharmacy and Pharmaceutical Sciences. "The continuing emergence of M. tuberculosis strains resistant to all existing, affordable drug treatments requires the development of novel, effective and inexpensive drugs.

The newly developed TB-drugome may help that effort, Bourne said, by identifying new M. tuberculosis protein targets that can be perturbed by a variety of existing drugs prescribed for other purposes.

Sarah Kinnings at the University of Leeds and a team of scientists at UC San Diego, led by Bourne (who is also associate director of the RCSB Protein Data Bank) and research scientist Lei Xie, PhD, used a novel computational strategy to investigate whether any existing drugs were able to bind to any of the approximately 40 percent of proteins in the M. tuberculosis proteome with decipherable three-dimensional structures.

The researchers not only discovered that approximately one-third of the drugs examined may have the potential to be repurposed to treat tuberculosis, but also that many currently unexploited M. tuberculosis proteins could serve as novel anti-tubercular targets. This finding led the investigators to construct a complex network of drug-target interactions a TB-drugome available to all scientists.

While this new computational,
'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study provides treatment hope for long term effects of brain trauma
2. 100-million-year-old mistake provides snapshot of evolution
3. UF research provides new understanding of bizarre extinct mammal
4. Study provides data that can inform Atlantic sturgeon recovery efforts
5. Protein provides link between calcium signaling in excitable and non-excitable cells
6. Going green: New program provides vital support for plant scientists
7. Hair provides proof of the link between chronic stress and heart attack
8. LSUHSC pediatric weight expert provides obesity trinity answers
9. Special edition journal provides new perspectives and guidance for managing white pine blister rust
10. Huntingtons disease discovery provides new hope for treatment
11. De La Rue Provides Second-Generation ePassport for Malta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... emulsions are crucial for providing essential fatty acids ... intravenous feeding. There has been concern that soybean-based ... damage due to its composition. Combination lipid emulsions ... oil have been developed to address this concern. ... found that concern may be unwarranted, according to ...
(Date:7/22/2014)... both still images and video of artistic merit ... still images were chosen from more than 250 ... alumni representing more than 25 different University departments. ... submissions. , Zach Donnell, a graduate student in ... noted that the exhibit highlights the interplay between ...
(Date:7/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2014. Revenue for the ... 53% compared to $4.4 million in the same quarter last ... quarter of 2014 was $1.4 million compared to $0.5 million ... and operating income was driven by higher sales of software ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... a new door to developing drugs to slow the ... Edward A. Fon at the Montreal Neurological Institute and ... in the Department of Biochemistry at the Faculty of ... Parkin. Mutations in Parkin cause a rare hereditary form ...
... around and often organize into highly resilient communities known as ... pattern similar to many economies, according to a new study ... Washington. The study, published online May 8 in ... the strategy by which bacteria form the micro-colonies that become ...
... the Southern Appalachian region of the United States could ... study by U.S. Forest Service scientists at the Coweeta ... online in the journal Ecological Applications and ... woolly adelgid, an exotic invasive insect, has caused widespread ...
Cached Biology News:Unleashing the watchdog protein 2Study finds that bacteria organize according to 'rich-get-richer' principle 2Study finds that bacteria organize according to 'rich-get-richer' principle 3Loss of eastern hemlock will affect forest water use 2
(Date:7/23/2014)... 2014 Shire plc (LSE: ... specialty biopharmaceutical company, and ArmaGen, a US privately ... and collaboration agreement for AGT-182, an investigational enzyme ... both the central nervous system (CNS) and somatic ... This collaboration strengthens Shire,s rare disease pipeline of ...
(Date:7/23/2014)... -- GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and ... medical marijuana dispensary locations in Las Vegas, Nevada ... Clark County, Nevada dispensary for which the ... GrowBLOX Sciences, CEO Craig Ellins stated, ... dispensaries in the City of Las Vegas ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... Group Limited ("Cordlife"), a multi-product healthcare company catering to the mother ... forces in assisting patients across the PRC, Singapore ... , India , the Philippines ...
Breaking Biology Technology:Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Sofinnova Raises $500 Million Biotech Venture Fund 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Up 14 Percent over Third Quarter 2007 ... Earnings Guidance, Introduces 2009 Adjusted Net Income Guidance, ... Cephalon, Inc. (Nasdaq:,CEPH) today reported third quarter 2008 sales ... third quarter of 2007, and at the high,end of the ...
... NVAX ) a clinical-stage vaccine company, announced today ... be presenting at,the BIO Investor Forum 2008 at 8:30 ... in San Francisco, California. Dr. Singhvi will provide an,overview ... to the live presentation can be accessed via the ...
... Antibiotics Ltd., the,developer of novel polymyxin derivatives ... Gram-negative bacteria, revealed today animal,efficacy and pharmacokinetic ... 48th,Annual ICAAC/IDSA 46th Annual Meeting in Washington, ... series of novel polymyxin (NAB),compounds (Vaara M. ...
Cached Biology Technology:Cephalon Reports Another Strong Quarter 2Cephalon Reports Another Strong Quarter 3Cephalon Reports Another Strong Quarter 4Cephalon Reports Another Strong Quarter 5Cephalon Reports Another Strong Quarter 6Cephalon Reports Another Strong Quarter 7Cephalon Reports Another Strong Quarter 8Cephalon Reports Another Strong Quarter 9Cephalon Reports Another Strong Quarter 10Cephalon Reports Another Strong Quarter 11Cephalon Reports Another Strong Quarter 12Cephalon Reports Another Strong Quarter 13Cephalon Reports Another Strong Quarter 14Cephalon Reports Another Strong Quarter 15Cephalon Reports Another Strong Quarter 16Cephalon Reports Another Strong Quarter 17Cephalon Reports Another Strong Quarter 18Cephalon Reports Another Strong Quarter 19Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008 2Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008 3
...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: